SLC5A2 and Hypoglycemia: Glucagonlike peptide-1 receptor agonists (GLP-1RA), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and dipeptidyl peptidase-4 inhibitors (DPP-4i) are associated with low rates of hypoglycemia, and postmarketing trials of GLP-1RA and SGLT2i also demonstrated that these drugs improved cardiovascular, kidney, and mortality outcomes.8,9,10,11,12,13,14,15,16,17,18,19,20,21